ReCAP

Highlights in Esophageal Research From ACG 2022 Highlights in esophageal diseases from ACG 2022 include data on use of dupilumab in eosinophilic esophagitis, achalasia as risk for esophageal cancer, and vonoprazan in nonerosive reflux disease.
November 15, 2022
Key Abstracts in COPD From CHEST 2022 Key abstracts in COPD from CHEST 2022, as reported by Dr Nicola Hanania, focus on spirometry use, exacerbation risks, home rehabilitation, and triple therapy after a second moderate exacerbation.
November 09, 2022
Highlights in Asthma Therapy From CHEST 2022 From CHEST 2022, Dr Navitha Ramesh reports key data on biologic therapies for asthma patients, including results from the CLEAR study and trials on omalizumab, benralizumab, and tezepelumab.
November 09, 2022
Highlights in Corneal Disorders From AAO 2022 Key data in corneal disorders from AAO include a nontransplant therapy for Fuchs dystrophy, data on corneal adverse events from a myeloma drug, and positive data on lotilaner for Demodex blepharitis.
October 21, 2022
Myasthenia Gravis Highlights From AANEM Data on therapeutic advances, including Fc receptor antagonists and complement inhibitors, top the myasthenia gravis highlights from AANEM 2022. Also reported is the effect of COVID-19 on MG patients.
October 14, 2022
Updates on Glycemic Control in Type 2 Diabetes From EASD 2022 Updates on glycemic control for type 2 diabetes from EASD 2022 focus on ADA/EASD guidelines on hyperglycemia and results of a 44-year prospective study of diabetes, as reported by Dr Anne Peters.
October 14, 2022
Key Data on Comorbidities in Type 2 Diabetes From EASD 2022 From EASD 2022, Dr Carol Wysham reports on advancing research for patients with type 2 diabetes and comorbidities, including nonalcoholic fatty liver disease and cardiovascular and renal disease.
October 14, 2022
Advances in Insulin Therapy for Type 2 Diabetes From EASD 2022 From EASD 2022, Dr Anne Peters reports on the latest updates on insulin therapy for T2D, including the data from the ONWARDS 2 trial and a subanalysis of the SoliMix trial.
October 12, 2022
Highlights in Advanced NSCLC From ESMO 2022 Highlights in NSCLC from ESMO 2022 include sotorasib in KRAS G12C mutated disease, 5-year data on pembrolizumab, and novel treatment combinations in EGFR-mutated tumors, as discussed by Jack West.
October 05, 2022
Key Data on Early NSCLC From ESMO 2022 Osimertinib dosing periods, the use of ctDNA to predict recurrence, and the role of air pollution in promoting lung cancer are among the key topics from ESMO Congress 2022 discussed by Dr Jack West.
October 04, 2022
Psoriasis Highlights From EADV 2022 A new topical treatment for psoriasis, tapinarof, was shown to be safe and effective at EADV 2022. Other key psoriasis data spanned pustular psoriasis, HIV, mental health, and smoking as a risk factor.
October 03, 2022
Atopic Dermatitis Highlights From EADV 2022 Highlights in atopic dermatitis from EADV include efficacy of dupilumab in clinical practice, JAK inhibitors upadacitinib and baricitinib, and a 28-country assessment of AD burden of disease.
October 03, 2022
Updates in Renal Cell Carcinoma From ESMO 2022 Positive results with triplet therapy, three adjuvant immunotherapy failures, and promising novel combinations are some of the updates from ESMO Congress 2022 discussed by Dr Eric Jonasch.
September 30, 2022
Updates in Heart Failure From ESC 2022 Advances in prognosis, the role of heart rate in mortality risk, and the application of heart failure guidelines are some of the updates from ESC 2022 discussed by Prof Wolfram Doehner.
September 20, 2022
Advances in Diabetes and Heart Disease From ESC 2022 The mortality risk of diabetes, the consistent efficacy of dapagliflozin, and adherence to SGLT2 inhibitors and GLP-1R agonists are some highlights from ESC 2022 chosen by Professor Pardeep Jhund.
September 14, 2022
Key Abstracts in Dementia Science From AAIC 2022 Key abstracts from AAIC 2022, as reported by Dr Michael Rafii, focus on crenezumab in autosomal dominant Alzheimer's disease and AD biomarkers in diabetes, Down syndrome, and persons with poor sleep.
August 24, 2022
Multiple Sclerosis Highlights From EAN 2022 Key presentations in multiple sclerosis at EAN 2022 included updated EAN-ECTRIMS treatment guidelines, prognostic biomarker findings, and data on BTK inhibitors in RRMS, as reported by Prof Jens Kuhle.
July 27, 2022
Advances in Thrombosis and Hemostasis From EHA 2022 Thrombosis and hemostasis highlights from EHA 2022 include fracture risk, treatment tapering, a novel drug in ITP, and management of bleeding risk in cancer, as discussed by Dr Benjamin Brenner.
July 07, 2022
Highlights in Early Breast Cancer From ASCO 2022 Highlights in early breast cancer from ASCO 2022 include results from NeoSTAR in triple-negative disease and 8-year follow-up of the ASTRRA study in ER+/HER2- patients, as reported by Dr Ann Partridge.
July 05, 2022
Highlights in Renal Cell Carcinoma From ASCO 2022 Dr Brian Rini, of Vanderbilt University, reports on key studies in renal cell cancer from ASCO 2022, including results from the EVEREST and CheckMate 9ER trials, and data on a novel AXL inhibitor.
July 05, 2022